跳至主要内容
临床试验/NL-OMON51996
NL-OMON51996招募中不适用

Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I multicenter feasibility and safety study - Fluorescence endoscopy in esophageal cancer

niversitair Medisch Centrum Groningen0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Lesion suspected for locally advanced EC (cT1b-4a N0-3 M0)
  • - Indication for neoadjuvant therapy
  • - Age >= 18 years;
  • - Written informed consent.

排除标准

  • - Medical or psychiatric conditions that compromise the patient*s ability to
  • give informed consent according to treating medical physician;
  • - Concurrent uncontrolled medical conditions according to treating medical
  • - Medical history of auto-immune disease
  • - Pregnancy or breast feeding. A negative pregnancy test must be available for
  • women of childbearing potential (i.e. premenopausal women with intact
  • reproductive organs and women less than two years after menopause);
  • - Irradical endoscopic mucosal resection (EMR) or endoscopic submucosal
  • (ESD) of the primary tumor prior to start of neoadjuvant chemoradiotherapy
  • according to the patient*s medical history;
  • - Received a different investigational drug within 30 days prior to the dose of
  • durvalumab-IRDye680LT according to the patient*s medical history;
  • - History of infusion reactions to durvalumab or other monoclonal antibodies
  • according to the patient*s medical history;

研究者

相似试验